Kura Oncology CEO Troy Wilson acquires 100,000 common shares valued at $1,239,000

• Kura Oncology President and CEO Troy Edward Wilson disclosed a purchase of 100,000 common shares at a weighted average price of $12.39.
• The shares were reported as held indirectly through the One Fish Two Fish Revocable Trust.
• Wilson’s reported post-transaction holdings included 435,456 shares held directly, 479,194 shares held via the trust.
• Separate indirect holdings of 300,000 shares were reported through the Lorax Charitable Remainder Unitrust.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-363812), on August 24, 2026, and is solely responsible for the information contained therein.